15 . 04 .2020
Press release
Galderma demonstrates continued commitment to aesthetic education by offering new series of digital webinars*
04 . 03 .2020
Press release
Galderma Announces an Acceleration of its Growth and Expansion Plans to Support Aesthetic Providers
03 . 03 .2020
Press release
Differin® Launches Clear90™ App, to Support People with Acne on Their Clear Skin Journey as Part of Third-Annual Retinoid Education Week
20 . 02 .2020
Press release
Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis
20 . 12 .2019
Press release
Galderma receives a positive outcome through the European Decentralised Procedure for AKLIEF® (trifarotene 50 mcg/g cream), the first new retinoid molecule for acne in the European Union in 25 years
09 . 12 .2019
Press release
Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis
24 . 10 .2019
Press release
Galderma Demonstrates Robust Aesthetic Innovation Pipeline with Initiation of Seven New Clinical Studies
24 . 10 .2019
Press release
Fort Worth’s Galderma, Maker of Cetaphil, Presents the 5th Annual Wonder Run 5K and Kids 1K to Benefit Children’s Skin Disease Foundation
21 . 10 .2019
Press release
Face Up To Rosacea: Galderma launches new campaign to empower and equip rosacea patients to discuss the true burden of their disease with a dermatologist
10 . 10 .2019
Press release
Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis